UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis

The New England journal of medicine, 1989-11, Vol.321 (19), p.1285

1989

Volltextzugriff (PDF)

Next European Torus General Description and Layout

Fusion technology, 1988-07, Vol.14 (1), p.49-57

1988

Volltextzugriff (PDF)

Next European Torus Plasma Exhaust and Fuel Processing Systems

Fusion technology, 1988-07, Vol.14 (1), p.178-186

1988

Volltextzugriff (PDF)

Spatiotemporal control of liquid crystal structure and dynamics through activity patterning

Nature materials, 2021-06, Vol.20 (6), p.875-882

2021

Volltextzugriff (PDF)

Next European Torus In-Vessel Components

Fusion technology, 1988-07, Vol.14 (1), p.82-144

1988

Volltextzugriff (PDF)

Authors

Fusion technology, 1988-07, Vol.14 (1), p.1-12

1988

Volltextzugriff (PDF)

Authors

Fusion technology, 1988-07, Vol.14 (1), p.1-12

1988

Volltextzugriff (PDF)

Motor crosslinking augments elasticity in active nematics

Soft matter, 2024-03, Vol.2 (11), p.248-249

2024

Volltextzugriff (PDF)

The Immunological Synapse Balances T Cell Receptor Signaling and Degradation

Science (American Association for the Advancement of Science), 2003-11, Vol.302 (5648), p.1218-1222

2003

Volltextzugriff (PDF)

Local Fluctuations in Solution: Theory and Applications

Advances in Chemical Physics, 2013-01, p.311-372

2013

Volltextzugriff (PDF)

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS7593-TPS7593

2022

Volltextzugriff (PDF)

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)

Blood, 2021-11, Vol.138 (Supplement 1), p.4776-4776

2021

Volltextzugriff (PDF)

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7500-7500

2023

Volltextzugriff (PDF)

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7006-7006

2023

Volltextzugriff (PDF)

Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.32-32

2021

Volltextzugriff (PDF)

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Blood, 2018-11, Vol.132 (Supplement 1), p.1453-1453

2018

Volltextzugriff (PDF)

A phase 1 dose escalation study of the IDH1 m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7009-7009

2018

Volltextzugriff (PDF)

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Blood, 2018-11, Vol.132 (Supplement 1), p.1452-1452

2018

Volltextzugriff (PDF)

Advances in chemical physics

2016

Volltextzugriff (PDF)

Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years

Epilepsy & behavior, 2014-12, Vol.41, p.164-170

2014

Volltextzugriff (PDF)

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

Journal of the National Comprehensive Cancer Network, 2022-02, Vol.20 (2), p.106

2022

Volltextzugriff (PDF)

An Approach To “Quantumness” In Coherent Control

Advances in Chemical Physics, 2017, p.39-135

2017

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(30)

Publikationsform

Sprache

Englisch
(43)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Physical Sciences
(14)
Physics
(14)
Physics, Atomic, Molecular & Chemical
(12)
Humans
(10)
Life Sciences & Biomedicine
(9)
Adult
(7)
Clinical Neurology
(7)
Neurosciences & Neurology
(7)
Biological And Medical Sciences
(5)
Female
(5)
Neurology
(5)
Technology
(5)
Child
(4)
Coherent Control
(4)
Medical Sciences
(4)
Nervous System
(4)
Adolescent
(3)
Chemistry
(3)
Electroencephalography
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis

Next European Torus General Description and Layout

Next European Torus Plasma Exhaust and Fuel Processing Systems

Spatiotemporal control of liquid crystal structure and dynamics through activity patterning

Next European Torus In-Vessel Components

Authors

Authors

Motor crosslinking augments elasticity in active nematics

The Immunological Synapse Balances T Cell Receptor Signaling and Degradation

Local Fluctuations in Solution: Theory and Applications

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance)

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703

Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

A phase 1 dose escalation study of the IDH1 m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Advances in chemical physics

Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8 years

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

An Approach To “Quantumness” In Coherent Control

Suchergebnisse filtern